RSS   Newsletter   Contact   Advertise with us
Post Online Media

Onconova Therapeutics promotes Steven M. Fruchtman to CEO

Share on Twitter Share on LinkedIn
Staff Writer | Newtown, Pa., USA |
Onconova TherapeuticsOnconova Therapeutics, a phase 3-stage biopharmaceutical company, announced the appointment of Steven Fruchtman as chief executive officer and a member of the board of directors.
Dr. Fruchtman has served as President of Onconova since June 2018, and originally joined the Company in January 2015 as Chief Medical Officer.

Previously, Dr. Fruchtman held senior leadership positions in pharmaceutical and biotechnology companies and academia.

Dr. Fruchtman is a board certified hematologist, who specialized in bone marrow diseases and stem cell transplantation.

He served with increasing leadership responsibilities at Ortho Biotech, Novartis, and biotechnology companies leading to successful clinical trial completion and regulatory approvals for a number of new chemical entities in various malignancies.

Prior to his transition to industry, he served as the Director of the Myeloproliferative Disorder Program at The Mount Sinai Hospital in New York City, a Center of Excellence, and established the Stem Cell Transplant Program there.

Dr. Fruchtman received his Bachelor of Arts with Honors from Cornell University, and his M.D. from New York Medical College.

He was recently named to the Board of The Bone Marrow Foundation.


 LATEST MOVES FROM Pennsylvania 


POST Online Media Contact